13 November 2002 17:17 [Source: ICIS news]
LONDON (CNI)--UK pharmaceuticals firm Antisoma announced Wednesday a 30% rise in fiscal first quarter pre-tax losses to £3.01m ($4.78m/Euro4.72m), citing as the main reason higher research and development (R&D) expenses.
Revenues for the three months to 30 September fell 27% to £358 000. These came from US group Abbot Laboratories for the development of the cancer drug pemtumomab.
Operating expenses rose 22% to £3.55m, with R&D expenses up 33% at £2.65m as manufacturing and pre-clinical developmental costs grew due to additional products in the pipeline.
The company had £15.4m in cash and cash equivalents on 30 September 2002, down from £18.9m on 30 June.
Chairman Barry Price said: “The company achieved an important milestone during the quarter by reaching the target for recruitment of patients into our phase III trial of pemtumomab in ovarian cancer. An independent analysis has indicated that we can expect to complete this major study before the end of 2004.”
He added: “As well as significant progress on our lead product, the pipeline has been further reinforced by the receipt of new patents, and our management team has been enhanced by the appointment of Miroslav Ravic as chief clinical officer [in September].”
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections